Xenetic Biosciences Q2 net loss $1.3M; cash $7.3M; DNase program advancing

Xenetic Biosciences, Inc.

2024-Q2 EPS reported -$1.60 revenue$1,237,221

Net loss of $1.3M for Q2 2024; R&D expenses flat at $0.9M; G&A up 19.5% to $1.1M on severance.
Royalty payments from Takeda sublicense of PolyXen platform were $0.7M, up 11.6% YoY.
Cash balance $7.3M at quarter end; expected to fund operations into clinical development.
Preclinical studies for DNase oncology platform ongoing; data expected before year end.
Advancing towards Phase 1 clinical proof-of-concept in pancreatic carcinoma and solid tumors.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.